Find, compare & contact
Bioymifi
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Bioymifi API 1420071-30-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Bioymifi. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Bioymifi
- Synonyms:
- 5-(5-((3-(4-bromophenyl)-2-imino-4-oxothiazolidin-5-ylidene)methyl)furan-2-yl)isoindoline-1,3-dione , 5-[5-[(Z)-[3-(4-bromophenyl)-2-imino-4-oxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]isoindole-1,3-dione
- Cas Number:
- 1420071-30-2
- DrugBank number:
- DB17493
General Description:
Bioymifi, identified by CAS number 1420071-30-2, is a notable compound with significant therapeutic applications. Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.
Mechanism of Action:
Bioymifi functions by: In cancer cells, tumor necrosis factor (TNF)-related apoptosis-induced ligand (TRAIL) initiates apoptosis by binding to death receptor 5 (DR5). In contrast, normal cells express high levels of decoy receptors (DcRs) that partially or completely lack the functional death domain (DD). Therefore, the binding of TRAIL on normal cells does not induce cell death. Because of this, small molecules that mimic the activity of TRAIL may have the potential to act as chemotherapeutic agents. Bioymifi mimics the activity of TRAIL, and upon binding to the extracellular domain (ECD) of DR5, it induces clustering and aggregation in cancer cells, leading to apoptosis. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Bioymifi is categorized under the following therapeutic classes: Acids, Carbocyclic, Heterocyclic Compounds, Fused-Ring, Imides, Isoindoles, Phthalic Acids, Receptors, TNF-Related Apoptosis-Inducing Ligand, agonists, Sulfur Compounds, Thiazoles. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Bioymifi is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
